Cybin, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sumant Kulkarni from Canaccord Genuity maintained a Buy rating on the stock and has a $70.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sumant Kulkarni has given his Buy rating due to a combination of factors surrounding Cybin’s promising pipeline and upcoming milestones. The company is advancing its CYB003 program, a deuterated psilocin analog, which is in Phase 3 trials for major depressive disorder. The expectation of reporting top-line data from these trials in the coming years and the potential filing of a new drug application by the end of 2027 are significant catalysts for the stock.
Furthermore, Cybin’s CYB004, a deuterated DMT, is in Phase 2 trials for generalized anxiety disorder, with data expected in 2025. Although the valuation does not currently account for CYB004, the progress in CYB003 and the substantial market opportunity in treating major depressive disorder provide a strong basis for the Buy rating. The analyst’s confidence is bolstered by encouraging Phase 2 results and the anticipation of key data releases, which could drive the stock’s performance.